"None of these headwinds can be faced without us bending. From my perspective, this move is a response to those changes, and it demonstrates our ability to be able to meet a challenge - it is important because it is going to continue," he told BioPharmaDispatch.
Dennis Bastas on Arrotex and creating the largest company by volume in PBS history
July 11, 2019 Latest NewsBioPharmaDispatch ExecutiveNews of the Day
Latest Video
New Stories
-
The private market might do what two decades of PBS reform attempts couldn't
October 12, 2026 - - Latest News -
The full set of numbers tell the story and reveal the massive funding shortfall
October 12, 2026 - - Latest News -
Private prescription market heads towards $4 billion as PBS spending stalls
October 12, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News
